Noureddin, Mazen
Sanyal, Arun J.
Article History
First Online: 31 October 2018
Compliance with Ethical Standards
:
: Arun J. Sanyal reports grants and other from Gilead, grants from Intercept, grants and other from Novartis, grants from Merck, grants and other from BMS, grants from Tobira, grants from Echosense, other from Sanyal Bio, other from Genfit, other from Tiziana, other from Galectin, other from Nitto Denko, other from Nimbus, other from Aredlyx, other from Vivelyx, other from Teva, other from Canfite, other from Boehringer Ingelheim, other from Pfizer, other from Salix, other from Enyo, other from uptodate, other from Natural Shield, other from Durect, other from Exhalenz, other from Hemoshear, and other from Akarna, outside the submitted work. Mazen Noureddin has been on the advisory board or a speaker for EchoSens North America, OWL, Gilead, Intercept, Novartis and Allergan. He has been a speaker for: Simply Speaking, Echosens, Alexion and Abbott. He has received research support from: Allergan, Gilead, Galmed, Galectin, Genfit, Conatus, Intercept, Enanta, Zydus, and Shire; Mazen Noureddin is a minor shareholder of Anaetos.
: This article does not contain any studies with human or animal subjects performed by any of the authors.